Virtu Financial’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$867K Buy
+14,322
New +$1.01M 0.03% 359
2026
Q1
– Sell
-13,811
Closed -$584K – 2075
2025
Q4
$584K Buy
+13,811
New +$773K 0.02% 540
2024
Q3
– Sell
-5,004
Closed -$93K – 1709
2024
Q2
$93K Buy
5,004
+3,887
+348% +$81.9K 0.01% 835
2024
Q1
$16K Buy
+1,117
New +$11.7K ﹤0.01% 1198
2023
Q3
– Sell
-912
Closed -$8K – 1684
2023
Q2
$8K Buy
+912
New +$9.7K ﹤0.01% 1371
2023
Q1
– Sell
-1,093
Closed -$37K – 1894
2022
Q4
$37K Buy
+1,093
New +$52.9K ﹤0.01% 1138
2019
Q4
$502K Buy
+1,551
New +$450K 0.05% 425
2019
Q3
– Sell
-785
Closed -$419K – 1693
2019
Q2
$419K Buy
+785
New +$394K 0.02% 614
2015
Q3
– Sell
-1,527
Closed -$287K – 376
2015
Q2
$287K Buy
+1,527
New +$263K 0.03% 267
2014
Q4
– Sell
-1,056
Closed -$191K – 365
2014
Q3
$191K Buy
+1,056
New +$202K 0.02% 275

Other funds holding NKTR

Virtu Financial's NKTR Position: Q3 2026 in Review

Virtu Financial opened a new position in Nektar Therapeutics (NKTR) in Q3 2026: 14,322 shares worth $867K. The stake represents 0.03% of the portfolio and ranks #359 among its holdings. This is a return to the name: Virtu Financial previously reported a position in NKTR as recently as Q4 2025.

Virtu Financial first reported a position in NKTR in Q3 2014 and has held it in 10 quarters since. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Virtu Financial held 14,322 shares of Nektar Therapeutics worth $867K as of Q3 2026.
  • Nektar Therapeutics was a new Virtu Financial position in Q3 2026.
  • Nektar Therapeutics made up 0.03% of Virtu Financial's portfolio in Q3 2026, its #359 holding.
  • Virtu Financial first reported a position in Nektar Therapeutics in Q3 2014 and has held it in 10 quarters since.
  • 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Virtu Financial's 13F filing for Q3 2026, filed 17 Nov 2026.